GlassScriptPhysician profile
Periyanan Vaduganathan
NPI 1518962588
$4,728.20
in general payments reported to CMS, 2019-2025
28 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $374 · 2021: $582 · 2022: $740 · 2023: $1,129 · 2024: $774 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.09 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $977.95 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $802.40 | 2020-2025 | Mylux Patient Kit With Mobile Device, Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $636.00 | 2019-2025 | |
| Pfizer INC. | $367.65 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $289.70 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $269.53 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $248.56 | 2019-2024 | Camzyos |
| Amgen INC. | $189.67 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $137.79 | 2021-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $106.86 | 2019-2025 | Farxiga |
| Impulse Dynamics (USA) INC. | $78.69 | 2023 | Optimizer |
| Novo Nordisk INC | $66.95 | 2022-2024 | Ozempic |
| Abbott Laboratories | $64.08 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $62.70 | 2019-2020 | |
| Amarin Pharma, INC. | $56.13 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $49.19 | 2023-2024 | Inpefa |
| Abiomed | $43.37 | 2022 | |
| Scpharmaceuticals INC. | $42.32 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $39.92 | 2024 | Uptravi, Opsumit |
| Biotronik INC. | $36.58 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.17 | 2025 | |
| Edwards Lifesciences Corporation | $26.88 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Agepha Pharma Fz LLC | $21.62 | 2024 | Lodoco |
| Esperion Therapeutics, INC. | $17.73 | 2025 | Nexletol |
| Lilly USA, LLC | $17.71 | 2025 | Zepbound |
| Kiniksa Pharmaceuticals, LTD. | $17.56 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $17.42 | 2024 | Arcalyst |
| Gilead Sciences, INC. | $15.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Periyanan Vaduganathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.